MLVPX
Price
$18.63
Change
-$0.43 (-2.26%)
Updated
Apr 3 closing price
Net Assets
356.86M
VFINX
Price
$498.00
Change
-$25.30 (-4.83%)
Updated
Apr 3 closing price
Net Assets
1.4T
Ad is loading...

MLVPX vs VFINX

Header iconMLVPX vs VFINX Comparison
Open Charts MLVPX vs VFINXBanner chart's image
MFS Low Volatility Equity R3
Price$18.63
Change-$0.43 (-2.26%)
VolumeN/A
Net Assets356.86M
Vanguard 500 Index Investor
Price$498.00
Change-$25.30 (-4.83%)
VolumeN/A
Net Assets1.4T
MLVPX vs VFINX Comparison Chart
Loading...
View a ticker or compare two or three
VS
MLVPX vs. VFINX commentary
Apr 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MLVPX is a Hold and VFINX is a Hold.

Ad is loading...
FUNDAMENTALS
Fundamentals
VFINX has more cash in the bank: 1.4T vs. MLVPX (357M). VFINX pays higher dividends than MLVPX: VFINX (1.24) vs MLVPX (0.91). MLVPX was incepted earlier than VFINX: MLVPX (11 years) vs VFINX (49 years). MLVPX (0.94) is less costly to investors than VFINX (0.14). MLVPX is a more actively managed with annual turnover of: 25.00 vs. VFINX (2.00). MLVPX (0) and VFINX (0) have matching initial minimum investment requirements. VFINX annual gain was more profitable for investors over the last year : 8.85 vs. MLVPX (-3.27). VFINX return over 5 years is better than : 127.97 vs. MLVPX (49.38).
MLVPXVFINXMLVPX / VFINX
Total Expense Ratio0.890.14636%
Annual Report Gross Expense Ratio0.940.14671%
Fund Existence11 years49 years-
Gain YTD2.427-3.587-68%
Front LoadN/AN/A-
Min. Initial Investment00-
Min. Initial Investment IRAN/AN/A-
Net Assets357M1.4T0%
Annual Yield % from dividends0.911.2473%
Returns for 1 year-3.278.85-37%
Returns for 3 years-8.6023.83-36%
Returns for 5 years49.38127.9739%
Returns for 10 years82.46173.0448%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FRSLX23.77N/A
N/A
Nuveen Small/Mid Cap Growth Opp A
LMNOX39.31N/A
N/A
Patient Opportunity I
MNBIX19.37N/A
N/A
Manning & Napier Pro-Blend Extnd Term I
ALCBX11.95N/A
N/A
ALPS/Smith Balanced Opportunity C
POLIX44.45N/A
N/A
Polen Growth Institutional